A five year follow-up study of the use of clozapine in community practice

Australian and New Zealand Journal of Psychiatry

Volumn 36, Issue 6, 2002, Pages 780-786

  Drew, Leslie R H ^a   Griffiths, Kathleen M ^b   Hodgson, Donna M ^c  

^a UNIVERSITY OF SYDNEY   (Australia)

^b AUSTRALIAN NATIONAL UNIVERSITY   (Australia)

^c CANBERRA HOSPITAL   (Australia)

Author keywords

Clozapine; Community practice; Finance; Outcome; Treatment resistant schizophrenia

Indexed keywords

CLOZAPINE;

ADULT; ARTICLE; AUSTRALIA; CLINICAL ARTICLE; CLINICAL STUDY; COHORT ANALYSIS; COMMUNITY CARE; COMMUNITY MENTAL HEALTH; COST CONTROL; DETERIORATION; DOSE RESPONSE; DRUG USE; DRUG WITHDRAWAL; EMPLOYMENT; EXPERIENCE; FOLLOW UP; HEALTH CARE COST; HOSPITAL ADMISSION; HOSPITAL BED; HOSPITALIZATION; HUMAN; LIFE EVENT; MEDICAL INFORMATION; MEDICAL RECORD; MENTAL HEALTH; PRESCRIPTION; PSYCHIATRIST; SCHIZOPHRENIA; SIDE EFFECT; SUICIDE; TREATMENT OUTCOME;

EID: 0036906563     PISSN: 00048674     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1614.2002.01091.x     Document Type: Article

References (25)

1. Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for treatment resistant schizophrenia: a double-blind comparison with chlorpromazine. Archives of General Psychiatry 1988; 45:789-796.
2. Wahlbeck K, Cheine M, Essali MA. Clozapine versus typical neuroleptic medication for schizophrenia. The Cochrane Library. [Cited 22 November 2001.] Available from URL: http://gateway2.ovid.com/ovidweb.cgi
3. Barnes TRE, Joyce EM. Antipsychotic drug treatment: recent advances. Current Opinion in Psychiatry 2001; 14:25-37.
4. Chakos M, Lieberman J, Hoffman E, Bradfield D, Sheitman B. Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomised trials. American Journal of Psychiatry 2001; 158:518-526.
5. Aitcheson K, Kerwin RW. Cost-effectiveness of clozapine. A UK clinic-based study. British Journal of Psychiatry 1997; 171:125-130.
6. Dickson RA, Dalby JT, Williams R, Warden SJ. Hospital days in clozapine- treated patients. Canadian Journal of Psychiatry 1998; 43:945-948.
7. Drew LRH, Hodgson DM, Griffiths KM. Clozapine in community practice: a 3-year follow-up study in the Australian Capital Territory. Australian and New Zealand Journal of Psychiatry 1999; 33:667-675.
8. Honer WG. MacEwan GW, Kopala L et al. A clinical study of clozapine treatment and predictors of response in a Canadian sample. Canadian Journal of Psychiatry 1995; 40:208-211.
9. Pollack S, Woerner MG, Howard A et al. Clozapine reduces rehospitalisation among schizophrenia patients. Psychopharmacology Bulletin 1998; 34:89-92.
10. Erlandsen C. Clozapine for schizophrenia. Nordic Journal of Psychiatry 2000; 54:143-148.
11. Killian JG, Kristin K, Lawrence C, Celermajer DS. Myocarditis and cardiomyopathy associated with clozapine. Lancet 1999; 354:1841-1845.
12. Lieberman JA. Maximising clozapine therapy: managing side-effects. Journal of Clinical Psychiatry 1998; 59 (Suppl. 3):38-43.
13. Young CR, Bowers MB Jr, Mazure CM. Management of the adverse effects of clozapine. Schizophrenia Bulletin 1998; 24:381-390.
14. Singh B, Hawthorne G, Vos T. The role of economic evaluation in mental health care. Australian and New Zealand Journal of Psychiatry 2001; 35:104-117.
15. Revicki DA. Pharmacoeconomic evaluation of treatments for refractory schizophrenia: clozapine related studies. Journal of Clinical Psychiatry 1999; 60 (Suppl. 1):7-11.
16. Glazer WM, Bryan M, Johnstone BM. Pharmacoeconomic evaluation of antipsychotic therapy for schizophrenia. Journal of Clinical Psychiatry 1997; 58 (Suppl. 10):50-54.
17. Maynard A, Bloor K. Building castles on sands or quicksands? British Journal of Psychiatry 1998; 173 (Suppl. 36):12-18.
18. Taylor DM. Establishing cost-effectiveness of antipsychotic drugs. British Journal of Psychiatry 1997; 171:486.
19. Overall JE, Gorham DR. The Brief Psychiatric Ratings Scale. Psychological Reports 1962; 10:799-872.
20. Rosen A, Hadzi-Pavlovic D, Parker G. The Life Skills Profile: a measure assessing function and disability in schizophrenia. Schizophrenia Bulletin 1989; 15:325-337.
21. Keck PE, Strakowski SM, McElroy SL. The efficacy of atypical antipsychotics in the treatment of depressive symptoms, hostility, and suicidality in patients with schizophrenia. Journal of Clinical Psychiatry 2000; 61 (Suppl. 3):4-9.
22. Meltzer HY. Treatment of suicidality in schizophrenia. The clinical science of suicide prevention. Annals of the New York Academy of Sciences 2001; 932:44-60.
23. Reid WH, Mason M, Hogan T. Suicide prevention effects associated with clozapine therapy in schizophrenia and schizoaffective disorder. Psychiatric Services 1998; 49:1029-1033.
24. Sernyak MJ, Desai R, Stolar M, Rosenheck R. Impact of clozapine in completed suicide. American Journal of Psychiatry 2001; 158:931-937.
25. Stahl SM. Selecting an atypical antipsychotic by combining clinical experience with guidelines from clinical trials. Journal of Clinical Psychiatry 1999; 60 (Suppl. 10):31-41.